150 related articles for article (PubMed ID: 37673635)
21. Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report.
Wafa A; As'sad M; Liehr T; Aljapawe A; Al Achkar W
J Med Case Rep; 2017 Apr; 11(1):94. PubMed ID: 28385156
[TBL] [Abstract][Full Text] [Related]
22. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
23. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
[TBL] [Abstract][Full Text] [Related]
25. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
He Y; Zhang J; Zhang Y; Hu Z; Wang P; Gan W; Xie S; Qian M; Pui CH; Jiang H; Zhu X; Zhang H; Zhang W
Pediatr Blood Cancer; 2022 Aug; 69(8):e29724. PubMed ID: 35441457
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
28. Progress and Prospects in Pediatric Leukemia.
Madhusoodhan PP; Carroll WL; Bhatla T
Curr Probl Pediatr Adolesc Health Care; 2016 Jul; 46(7):229-241. PubMed ID: 27283082
[TBL] [Abstract][Full Text] [Related]
29. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
30. [Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
Shimada H
Rinsho Ketsueki; 2022; 63(7):799-804. PubMed ID: 35922951
[TBL] [Abstract][Full Text] [Related]
31. [Molecular genetics of acute lymphoblastic leukemia].
Tamai H; Inokuchi K
Rinsho Ketsueki; 2015 Mar; 56(3):253-60. PubMed ID: 25876777
[TBL] [Abstract][Full Text] [Related]
32. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.
Ben Abdelali R; Asnafi V; Petit A; Micol JB; Callens C; Villarese P; Delabesse E; Reman O; Lepretre S; Cahn JY; Guillerm G; Berthon C; Gardin C; Corront B; Leguay T; Béné MC; Ifrah N; Leverger G; Dombret H; Macintyre E
Haematologica; 2013 Nov; 98(11):1711-7. PubMed ID: 23831922
[TBL] [Abstract][Full Text] [Related]
33. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
34. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ; Narendran A; Neville KA
Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
[TBL] [Abstract][Full Text] [Related]
35. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of children and young adults with T-cell acute lymphoblastic leukemia/lymphoma who present in critical status.
Wayne NJ; Li Y; Chung P; Coffan K; Rheingold SR
Pediatr Blood Cancer; 2022 Apr; 69(4):e29457. PubMed ID: 34997812
[TBL] [Abstract][Full Text] [Related]
37. Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.
Graiqevci-Uka V; Behluli E; Spahiu L; Liehr T; Temaj G
Curr Pediatr Rev; 2023; 19(2):150-156. PubMed ID: 36056858
[TBL] [Abstract][Full Text] [Related]
38. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
39. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
40. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
Thomas X
Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
